A股異動 | 健康元(600380.SH)漲近6% 新冠疫苗加強針已在申報上市 能有效對抗奧密克戎
格隆匯2月21日丨健康元(600380.SH)高開高走,現漲幅擴大至近6%,報12.99元創逾一個月新高,總市值248億元。健康元公吿披露,公司控股子公司麗珠集團的控股子公司麗珠生物與中國科學院生物物理研究所合作研發的“重組新型冠狀病毒融合蛋白疫苗”(簡稱“V-01”)已完成序貫加強Ⅲ期臨牀試驗的中期主數據分析,並獲得了關鍵性數據。值得注意的是,V-01序貫加強三期臨牀試驗方案是全球首個針對奧密克戎研究序貫加強保護力的隨機、雙盲Ⅲ期臨牀試驗。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.